JO
ONCE

John Overdeck’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

John Overdeck’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-11,925
Closed -$924K – 3232
2015
Q1 		$924K Buy
+11,925
New +$687K ﹤0.01% 1632

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

John Overdeck's ONCE Position: Q2 2015 in Review

John Overdeck sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q2 2015, closing a stake of 11,925 shares — an estimated $924K sold.

John Overdeck first reported a position in ONCE in Q1 2015 and held it in 1 quarter. The position peaked at $924K in Q1 2015. 109 funds tracked by Wall St. Rank hold ONCE as of Q2 2015.

  • John Overdeck reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • John Overdeck sold 11,925 Spark Therapeutics, Inc. Common Stock shares in Q2 2015, an estimated $924K.
  • John Overdeck first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 1 quarter.
  • John Overdeck's Spark Therapeutics, Inc. Common Stock position peaked at $924K in Q1 2015.
  • 109 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q2 2015.

Based on Two Sigma Investments's 13F filing for Q2 2015, filed 14 Aug 2015.